• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.

作者信息

Hampel Paul J, Parikh Sameer A, Call Timothy G, Shah Mithun V, Bennani N Nora, Al-Kali Aref, Rabe Kari G, Wang Yucai, Muchtar Eli, Leis Jose F, Kenderian Saad S, Koehler Amber B, Schwager Susan M, Slager Susan L, Kay Neil E, Hanson Curtis A, Van Dyke Daniel L, Shi Min, Ding Wei

机构信息

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Division of Biomedical Statistics & Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

出版信息

Blood Cancer J. 2021 Mar 2;11(3):47. doi: 10.1038/s41408-021-00443-1.

DOI:10.1038/s41408-021-00443-1
PMID:33654067
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7925672/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58e1/7925672/cf0db3c470e4/41408_2021_443_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58e1/7925672/cf0db3c470e4/41408_2021_443_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58e1/7925672/cf0db3c470e4/41408_2021_443_Fig1_HTML.jpg

相似文献

1
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.维奈托克治疗复发的T细胞幼淋巴细胞白血病患者。
Blood Cancer J. 2021 Mar 2;11(3):47. doi: 10.1038/s41408-021-00443-1.
2
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.首例 T 细胞前淋巴细胞白血病中 BCL-2 抑制剂 venetoclax 的人体反应。
Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.
3
Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.超声检查对复发/难治性慢性淋巴细胞白血病患者维奈克拉治疗的反应评估
Leuk Res. 2021 Jan;100:106488. doi: 10.1016/j.leukres.2020.106488. Epub 2020 Nov 30.
4
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.维奈托克和伊布替尼用于复发/难治性慢性淋巴细胞白血病患者。
Blood. 2021 Feb 25;137(8):1117-1120. doi: 10.1182/blood.2020008608.
5
Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.维奈托克联合低甲基化药物治疗复发/难治性急性髓系白血病：来自单中心的病例系列。
J BUON. 2021 Sep-Oct;26(5):2026-2032.
6
Experience of using venetoclax in relapsed T- cell lymphoma.
Leuk Lymphoma. 2024 Oct;65(10):1538-1539. doi: 10.1080/10428194.2024.2363418. Epub 2024 Jun 17.
7
An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.波纳替尼联合维奈托克治疗复发/难治性费城染色体阳性急性淋巴细胞白血病的有效无化疗方案。
Am J Hematol. 2021 Jul 1;96(7):E229-E232. doi: 10.1002/ajh.26175. Epub 2021 Apr 12.
8
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.基于维奈克拉的疗法在异基因造血细胞移植后复发的急性髓系白血病中的挽救性应用。
Blood Cancer J. 2021 Mar 4;11(3):49. doi: 10.1038/s41408-021-00437-z.
9
Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.维奈克拉可穿透脑脊液，对合并中枢神经系统受累的慢性淋巴细胞白血病可能有效。
Haematologica. 2019 May;104(5):e222-e223. doi: 10.3324/haematol.2018.213157. Epub 2019 Feb 14.
10
The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data.抗菌预防对接受基于维奈克拉方案治疗的复发/难治性浆细胞异常患者结局的影响：真实世界数据。
Leuk Res. 2020 Oct;97:106429. doi: 10.1016/j.leukres.2020.106429. Epub 2020 Jul 30.

引用本文的文献

1
Effects of venetoclax, a BCL2 inhibitor, in systemic chronic active Epstein-Barr virus disease.BCL2抑制剂维奈克拉在系统性慢性活动性EB病毒病中的作用
Sci Rep. 2025 May 27;15(1):18569. doi: 10.1038/s41598-025-03719-9.
2
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.伊布替尼和维奈克拉治疗T-原淋巴细胞白血病疗效有限：一项2期国际研究的结果
Blood Adv. 2024 Feb 27;8(4):842-845. doi: 10.1182/bloodadvances.2023012248.
3
Clinical analysis of prolymphoblastic leukemia: the rare hematological malignancy in the elderly.

本文引用的文献

1
Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.T 记忆样 T-PLL 细胞的非典型效应功能是由 TCL1A 和 TCR 信号的协同作用塑造的。
Blood. 2020 Dec 10;136(24):2786-2802. doi: 10.1182/blood.2019003348.
2
Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.将表观遗传疗法与维奈克拉联合使用可克服T细胞幼淋巴细胞白血病中的阿仑单抗耐药性。一名26岁男性的病例报告，该患者既往有T细胞急性淋巴细胞白血病和胃肠道T淋巴瘤病史。
Acta Oncol. 2020 Dec;59(12):1547-1551. doi: 10.1080/0284186X.2020.1821913. Epub 2020 Sep 24.
3
幼淋巴细胞白血病的临床分析：老年人中罕见的血液系统恶性肿瘤。
Am J Transl Res. 2023 Sep 15;15(9):5653-5663. eCollection 2023.
4
T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.T 细胞前淋巴细胞白血病：诊断、发病机制与治疗。
Int J Mol Sci. 2023 Jul 28;24(15):12106. doi: 10.3390/ijms241512106.
5
Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact.T 细胞原淋巴细胞白血病的先进发病机制概念及其转化影响
Front Oncol. 2021 Nov 19;11:775363. doi: 10.3389/fonc.2021.775363. eCollection 2021.
6
Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias.劫持通路：成熟T细胞白血病的治疗前景
Hemasphere. 2021 Jun 1;5(6):e573. doi: 10.1097/HS9.0000000000000573. eCollection 2021 Jun.
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.
T细胞幼淋巴细胞白血病中对BCL2和MCL1的双重依赖。
Blood Adv. 2020 Feb 11;4(3):525-529. doi: 10.1182/bloodadvances.2019000917.
4
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.JAK/STAT激活的基因组改变是T细胞幼淋巴细胞白血病的一个标志。
Cancers (Basel). 2019 Nov 21;11(12):1833. doi: 10.3390/cancers11121833.
5
First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).维奈托克联合喷司他丁治疗T细胞幼淋巴细胞白血病（T-PLL）临床反应的首例报告
Leuk Lymphoma. 2020 Feb;61(2):445-449. doi: 10.1080/10428194.2019.1660967. Epub 2019 Sep 30.
6
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.T 细胞大颗粒淋巴细胞白血病的诊断、分期和治疗反应评估的共识标准。
Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10.
7
Ibrutinib and Venetoclax for First-Line Treatment of CLL.伊布替尼联合维奈托克用于初治 CLL 患者。
N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.
8
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.TCL1/ATM 对损伤反应的可操作扰动和表观遗传损伤构成 T-PLL 的基础。
Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.
9
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.首例 T 细胞前淋巴细胞白血病中 BCL-2 抑制剂 venetoclax 的人体反应。
Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.
10
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.高通量体外药物测试和突变分析发现 T-PLL 的新型药物敏感性。
Leukemia. 2018 Mar;32(3):774-787. doi: 10.1038/leu.2017.252. Epub 2017 Aug 14.